These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16104078)

  • 1. Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
    Geriatrics; 2005 Aug; 60(8):12. PubMed ID: 16104078
    [No Abstract]   [Full Text] [Related]  

  • 2. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
    Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N
    Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Diabetes Association - 65th Scientific Sessions. PPAR agents.
    Erlich R
    IDrugs; 2005 Aug; 8(8):608-10. PubMed ID: 16044361
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jun; 7(9):1229-33. PubMed ID: 16732709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
    Nissen SE; Wolski K; Topol EJ
    JAMA; 2005 Nov; 294(20):2581-6. PubMed ID: 16239637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muraglitazar (Bristol-Myers Squibb/Merck).
    Barlocco D
    Curr Opin Investig Drugs; 2005 Apr; 6(4):427-34. PubMed ID: 15898350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
    Charbonnel B
    Lancet; 2009 Jul; 374(9684):96-8. PubMed ID: 19515412
    [No Abstract]   [Full Text] [Related]  

  • 10. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecule of the month. Muraglitazar.
    Drug News Perspect; 2005 May; 18(4):284. PubMed ID: 16034485
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse events related to muraglitazar use in diabetes.
    Parra D; Beckey C; Thomas T
    JAMA; 2006 May; 295(17):1997-8; author reply 1998. PubMed ID: 16670403
    [No Abstract]   [Full Text] [Related]  

  • 13. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
    Cox SL
    Drugs Today (Barc); 2005 Sep; 41(9):579-87. PubMed ID: 16341289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One pill, two conditions.
    Kordella T
    Diabetes Forecast; 2005 Oct; 58(10):44. PubMed ID: 16299847
    [No Abstract]   [Full Text] [Related]  

  • 15. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selling safety--lessons from muraglitazar.
    Brophy JM
    JAMA; 2005 Nov; 294(20):2633-5. PubMed ID: 16239638
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Proceedings of a symposium. November 6-8, 2002, New York, New York, USA.
    Am J Med; 2003 Dec; 115 Suppl 8A():1S-120S. PubMed ID: 14678858
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
    Nathan DM; Buse JB; Davidson MB; Ferrannini E; Holman RR; Sherwin R; Zinman B
    Diabetes Care; 2008 Jan; 31(1):173-5. PubMed ID: 18165348
    [No Abstract]   [Full Text] [Related]  

  • 19. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes: assessing the pipeline.
    Lebovitz H
    Atheroscler Suppl; 2006 Apr; 7(1):43-9. PubMed ID: 16504599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.